Stock Detail
OREXIGEN THERAPEUTICS INC
Biotechnology
OREX @ Yahoo Finance | OREX Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.94 | $2.00 | $0.00 | 0.00% | 0.00 | $1.98 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.98 | $1.94 | 238,673 | 93.28M | 438,584 | 0.00 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 2.02 | 1.98 | 1.96 | 1.92 | 1.90 |
Stock Profile
Orexigen Therapeutics, Inc. operates as a biopharmaceutical company focusing on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. Its lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II development. These two product candidates are designed based on the company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. The company was founded in 2002 and is headquartered in San Diego, California.